NeOnc Technologies Prices $15M Registered Direct Offering With Institutional Investors

(RTTNews) – NeOnc Technologies Holdings, Inc. (NTHI) announced that it has entered into definitive securities purchase agreements with new and existing healthcare-focused institutional investors for a registered direct offering expected to generate approximately $15 million in gross proceeds.

Under the offering, NeOnc will sell 3,571,430 shares of common stock, or pre-funded warrants to purchase common stock in lieu thereof, together with warrants to purchase up to 3,571,430 additional shares.

The securities are being offered at a combined purchase price of $4.20 per share and accompanying warrant, or $4.1999 per pre-funded warrant and accompanying warrant.

Each pre-funded warrant will be exercisable upon issuance at an exercise price of $0.0001 per share and will expire when exercised in full.

Each accompanying warrant will be immediately exercisable at an exercise price of $4.20 per share and will expire five years from the date of issuance.

NeOnc expects to receive approximately $15 million in gross proceeds from the offering before deducting placement agent fees and other estimated offering expenses.

The offering is expected to close on or about September 10, 2026, subject to the satisfaction of customary closing conditions.

Roth Capital Partners and A.G.P./Alliance Global Partners are acting as co-placement agents for the offering.

The registered direct offering is being made pursuant to NeOnc’s shelf registration statement on Form S-3, which was previously filed with the U.S. Securities and Exchange Commission and became effective on April 9, 2026.

NeOnc said the offering is being made pursuant to a prospectus supplement and accompanying prospectus forming part of the effective registration statement.

NeOnc Technologies is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics designed to address challenges associated with overcoming the blood-brain barrier.

The company’s NEO drug development platform has generated a portfolio of drug candidates and delivery methods supported by patent protections extending to 2038.

The company said its proprietary chemotherapy agents have demonstrated positive effects in laboratory testing across multiple cancer types and in clinical trials involving malignant gliomas.

NeOnc’s NEO100 and NEO212 therapeutics are currently being evaluated in Phase 2 human clinical trials and are advancing under FDA Fast Track and Investigational New Drug status.

The company has also exclusively licensed a worldwide patent portfolio from the University of Southern California covering issued patents and pending applications related to NEO100, NEO212 and other products within the NeOnc patent family.

The licensed intellectual property covers multiple potential applications, including oncology and neurological conditions.

NeOnc said the financing will provide additional capital as it continues advancing its CNS-focused therapeutic pipeline and clinical development programs.

Currently, NTHI is trading at $3.63, down 10.81%.